In total, 6 ICIs have been approved for clinical use against NSCLC, including ipilimumab (a fully human IgG1 antibody targeting CTLA-4), pembrolizumab (a humanized, IgG4 antibody targeting PD-1), nivolumab (a fully human IgG4 antibody targeting PD-1), cemiplimab (a humanized monoclonal IgG4 targeting PD-1), atezolizumab (a humanized IgG1 antibody targeting PD-L1), and durvalumab (a humanized IgG1 antibody target PD-L1). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.